Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion type Assertion NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_head.
- NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion description "[Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_provenance.
- NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion evidence source_evidence_literature NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_provenance.
- NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion SIO_000772 19204207 NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_provenance.
- NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion wasDerivedFrom gad-20150221 NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_provenance.
- NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_assertion wasGeneratedBy ECO_0000203 NP140562.RAWMWj0chU9NtfpzjSPcdfJY8vd3dd8OZi9Pr2_e1BD2w130_provenance.